Nautilus Biotechnology posts first revenue, Q2 net loss narrows

Metric	Actual
Q2 loss per share	$0.11
Q2 net loss	$14.47 million
Q2 operating expenses	$15.94 million

The current average analyst rating on the shares is strong buy, with 2 strong buy or buy ratings and no hold, sell, or strong sell ratings.

The median 12-month price target is $4.00, about 141% above the July 27 closing price of $1.66.

Nautilus Biotechnology reported first revenue in the second quarter of 2026, driven by a grant from the Michael J. Fox Foundation and initial service sales under its Iterative Mapping Early Access Program.

The US proteomics platform developer said operating expenses fell 7% year over year, while the net loss narrowed slightly from the prior year.

The company said it shifted resources to accelerate proteoform applications in response to customer demand, without increasing overall spending.

Lower operating expenses reflected reduced salaries, stock-based compensation, and facilities costs.